CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to LNTH

Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)

Phase 2
Lantheus Holdings, Inc. (LNTH)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed / Refractory Osteosarcoma

View Full Landscape
Drug Information

Target Indication

Relapsed / Refractory Osteosarcoma

Clinical Trial

NCT07357519

Last updated: 10/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.